Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221903 · ClinicalTrials.gov registry record
The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA
A clinical trial of Burn and Regional Anesthesia, sponsored by University of Washington.
- Recruiting
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT07221903: Recruiting study of Burn and Regional Anesthesia, sponsored by University of Washington.
NCT07221903 is a study of Burn and Regional Anesthesia that is actively recruiting participants, run by University of Washington. The registered enrollment target is 10 participants, below the 52-participant average among 8 other Burn trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221903, a study of Burn and Regional Anesthesia, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Skin donor sites in patients undergoing split-thickness skin grafting surgeries can be very painful postoperatively. This site is most often the anterolateral thigh, the pain at which location can traditionally be covered by a fascia iliaca nerve block, although that comes with the disadvantage of losing motor functions in the femoral nerve distribution. The LAM nerve block, which is relatively new, aims to provide analgesia in the distribution of the lateral and anterior femoral cutaneous nerves. In short, this nerve block would decrease the sensation of the anterolateral thigh area without affecting the motor function of the leg. Investigators aim to study the consistency and coverage size of sensation changes by mapping out the area after the block in each patient.
Conditions Studied
Study Locations (1)
Washington
- Harborview Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2026-12-31 |
What NCT07221903 shows while recruiting
NCT07221903 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 52-participant average among 8 other Burn trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Burn appearing as the primary indexed condition, and to 0 interventions.
NCT07221903 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07221903 about?
NCT07221903 is a clinical study titled "The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA". Skin donor sites in patients undergoing split-thickness skin grafting surgeries can be very painful postoperatively. This site is most often the anterolateral thigh, the pain at which location can traditionally be covered by a fascia iliaca nerve block, although that comes with the disadvantage of l...
What is the current status of trial NCT07221903?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2025-10-22. Estimated completion is 2026-12-31.
What conditions does trial NCT07221903 study?
This clinical trial studies the following conditions: Burn, Regional Anesthesia, Skin Grafting.
Who is sponsoring clinical trial NCT07221903?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221903 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07221903's enrollment target sits among peer trials
10 8th of 8 higher than 1 of 8 other Burn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Paraffin Wax and Exercise Prospective
RECRUITING · NA
-
Utilizing 3D Imaging for Burn Wound Assessment
RECRUITING
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
-
Low-Dose Ketamine Infusion During Burn Wound Care
RECRUITING · Phase 4
-
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
ACTIVE NOT RECRUITING · NA
-
A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI